Persistent collection difficulties lead Mingde Biotech to face financial delisting conditions

MaticHoleFiller · 2026-04-06T21:17:09+00:00

Mingde Biology forecasts a net loss in 2025 due to difficulties in accounts receivable collections, which may trigger delisting due to financial reasons. The earnings revision shows a significant difference from the previous forecast, with post-pandemic revenue surges posing hidden risks. The company has expanded its business through acquisitions but faces financial challenges.

MaticHoleFiller

2026-04-06 21:17:09

Abstract generation in progress

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes